 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
15 March 1994 | Volume 120 Issue 6 | Pages 470-475
Objective: To determine if the presence of antiphospholipid antibody [aPL] in healthy pregnant women is associated with adverse pregnancy outcome, including 1) intrauterine fetal loss, 2) maternal pregnancy complications, 3) low birth weight, and 4) low 5-minute Apgar scores.
Design: Prospective cohort study in women with normal pregnancies.
Setting: Obstetrics clinic at the University of Colorado Health Sciences Center.
Patients: Eligible patients included 451 low-risk, nulliparous pregnant women who came to the obstetrics clinic before 25 weeks gestation; 408 were enrolled and 389 had blood drawn at the first prenatal visit and completed clinical follow-up.
Measurements: Blood for six aPL measures was drawn at the first prenatal visit and for 239 patients at delivery.
Results: Ninety-five patients (24.4%) had elevated aPL levels by one or more measures at the first prenatal visit: 15.8% of the aPL-positive and 6.5% of the aPL-negative patients experienced fetal loss (relative risk, 2.44; 95% CI, 1.29 to 4.62). However, an elevated IgG anticardiolipin antibody level at the first prenatal visit was the only aPL measurement that was significantly associated with fetal loss (relative risk, 3.5; CI, 1.56 to 8.07). Adjustment for confounding variables decreased the relative risk of aPL for fetal loss slightly, but the difference remained statistically significant. Neither a positive aPL result at the initial visit nor a positive result at delivery was associated with maternal complications of pregnancy, low birth weight, or low Apgar scores.
Conclusions: Patients with elevated aPL levels at their initial prenatal visit had an increase in fetal loss but no increase in maternal pregnancy complications, low birth weight, or low Apgar scores. Immunoglobulin G anticardiolipin antibody was the only single test of aPL significantly associated with fetal loss.
Author and Article Information
From the University of Colorado Health Sciences Center, Denver, Colorado; REAADS Medical Products, Westminster, Colorado.
ARTICLE
Antiphospholipid Antibodies in Predicting Adverse Pregnancy Outcome: A Prospective Study
Requests for Reprints: Anne Lynch, MB, Rheumatology Division, Box B115, University of Colorado Health Sciences Center, 4200 East 9th Avenue, Denver, CO 80262.
Acknowledgments: The authors thank the nursing staff of the Obstetrics Clinic and Labor Deck at UCHSC for their cooperation and help; Sue Stantejsky, Linda Larson, and Marianne McCormack for their help in preparing the manuscript; and Drs. Richard Hamman, Kent Heybourne, and Dan Eicher for their advice and guidance.
Grant Support: Rocky Mountain Chapter of the Arthritis Foundation.
This article has been cited by other articles:
|
|
 |
|
  I Giles, A Lambrianides, and A Rahman Examining the non-linear relationship between monoclonal antiphospholipid antibody sequence, structure and function Lupus, October 1, 2008; 17(10): 895 - 903. [Abstract] [PDF]
|
|
|
|
 |
|
 S. M. Bates, I. A. Greer, I. Pabinger, S. Sofaer, and J. Hirsh Venous Thromboembolism, Thrombophilia, Antithrombotic Therapy, and Pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 844S - 886S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Leanos-Miranda, G. Cardenas-Mondragon, A. Ulloa-Aguirre, I. Isordia-Salas, A. Parra, and J. Ramirez-Peredo Anti-prolactin autoantibodies in pregnant women with systemic lupus erythematosus: maternal and fetal outcome Lupus, May 1, 2007; 16(5): 342 - 349. [Abstract] [PDF]
|
|
|
|
 |
|
 I. Giles, N. Lambrianides, N. Pattni, D. Faulkes, D. Latchman, P. Chen, S. Pierangeli, D. Isenberg, and A. Rahman Arginine Residues Are Important in Determining the Binding of Human Monoclonal Antiphospholipid Antibodies to Clinically Relevant Antigens J. Immunol., August 1, 2006; 177(3): 1729 - 1736. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Lim, M. A. Crowther, and J. W. Eikelboom Management of Antiphospholipid Antibody Syndrome: A Systematic Review JAMA, March 1, 2006; 295(9): 1050 - 1057. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. S. Nielsen and O. B. Christiansen Prognostic impact of anticardiolipin antibodies in women with recurrent miscarriage negative for the lupus anticoagulant Hum. Reprod., June 1, 2005; 20(6): 1720 - 1728. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Lee, M. A. Brown, D. W. Branch, K. Ward, and R. M. Silver Anticardiolipin and Anti-{beta}2-Glycoprotein-I Antibodies in Preeclampsia Obstet. Gynecol., August 1, 2003; 102(2): 294 - 300. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Tincani, W Branch, R A Levy, J C Piette, H Carp, R S Rai, M Khamashta, and Y Shoenfeld Treatment of pregnant patients with antiphospholipid syndrome Lupus, July 1, 2003; 12(7): 524 - 529. [Abstract] [PDF]
|
|
|
|
 |
|
 L. Heilmann, G.-F. v. Tempelhoff, and K. Pollow Antiphospholipid Syndrome in Obstetrics Clinical and Applied Thrombosis/Hemostasis, April 1, 2003; 9(2): 143 - 150. [Abstract] [PDF]
|
|
|
|
|
|
G Roberts, M M Gordon, D Porter, A G Jardine, and I W Gibson Acute renal failure complicating HELLP syndrome, SLE and anti-phospholipid syndrome: successful outcome using plasma exchange therapy Lupus, April 1, 2003; 12(4): 251 - 257. [Abstract] [PDF]
|
|
|
|
|
|
M. Empson, M. Lassere, J. C. Craig, and J. R. Scott Recurrent Pregnancy Loss With Antiphospholipid Antibody: A Systematic Review of Therapeutic Trials Obstet. Gynecol., January 1, 2002; 99(1): 135 - 144. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Buyon, D. Nugent, E. Mellins, and C. Sandborg Maternal Immunologic Diseases and Neonatal Disorders NeoReviews, January 1, 2002; 3(1): e3 - 10. [Full Text] [PDF]
|
|
|
|
|
|
H. MASAMOTO, T. TOMA, K. SAKUMOTO, and K. KANAZAWA Clearance of Antiphospholipid Antibodies in Pregnancies Treated With Heparin Obstet. Gynecol., March 1, 2001; 97(3): 394 - 398. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. B. Goldstein, R. Adams, K. Becker, C. D. Furberg, P. B. Gorelick, G. Hademenos, M. Hill, G. Howard, V. J. Howard, B. Jacobs, et al. Primary Prevention of Ischemic Stroke : A Statement for Healthcare Professionals From the Stroke Council of the American Heart Association Circulation, January 2, 2001; 103(1): 163 - 182. [Full Text] [PDF]
|
|
|
|
 |
|
 R H W M DERKSEN, P. G DE GROOT, H K NIEUWENHUIS, and G C M L CHRISTIAENS How to treat women with antiphospholipid antibodies in pregnancy? Ann Rheum Dis, January 1, 2001; 60(1): 1 - 3. [Full Text]
|
|
|
|
 |
|
 L. B. Goldstein, R. Adams, K. Becker, C. D. Furberg, P. B. Gorelick, G. Hademenos, M. Hill, G. Howard, V. J. Howard, B. Jacobs, et al. Primary Prevention of Ischemic Stroke : A Statement for Healthcare Professionals From the Stroke Council of the American Heart Association Stroke, January 1, 2001; 32(1): 280 - 299. [Full Text] [PDF]
|
|
|
|
 |
|
 C. P. Mavragani, J. P. A. Ioannidis, A. G. Tzioufas, I. E. Hantoumi, and H. M. Moutsopoulos Recurrent pregnancy loss and autoantibody profile in autoimmune diseases Rheumatology, December 1, 1999; 38(12): 1228 - 1233. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Bizzaro, P. Pasini, and B. Finco False-Positive Reactions for IgA Anti-Phospholipid and Anti-{beta}2-Glycoprotein I Antibodies in Patients with IgA Monoclonal Gammopathy Clin. Chem., November 1, 1999; 45(11): 2007 - 2010. [Full Text] [PDF]
|
|
|
|
|
|
B.D. Kaider, C.B. Coulam, and R.G. Roussev Murine embryos as a direct target for some human autoantibodies in vitro Hum. Reprod., October 1, 1999; 14(10): 2556 - 2561. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. LYNCH, T. BYERS, W. EMLEN, D. RYNES, S. M. SHETTERLY, and R. F. HAMMAN Association of Antibodies to Beta2-Glycoprotein 1 With Pregnancy Loss and Pregnancy-Induced Hypertension: A Prospective Study in Low-Risk Pregnancy Obstet. Gynecol., February 1, 1999; 93(2): 193 - 198. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.D. Lockshin Review : Pregnancy loss and antiphospholipid antibodies Lupus, January 1, 1998; 7(2_suppl): S86 - S89. [Abstract] [PDF]
|
|
|
|
|
|
A. Lynch, J. Rutledge, J. Stephens, J. Murphy, R. Marlar, G. Davila, M. Santos, and W. Emlen Longitudinal measurement of anticardiolipin antibodies during normal pregnancy: a prospective study Lupus, October 1, 1995; 4(5): 365 - 369. [Abstract] [PDF]
|
|
|
|
|
|
T. Barbui and G. Finazzi Clinical Trials on Antiphospholipid Syndrome: What is Being Done and What is Needed? Lupus, August 1, 1994; 3(4): 303 - 307. [PDF]
|
|
|
|
|
|
M. D. Lockshin Antiphospholipid Antibody: Future Developments Lupus, August 1, 1994; 3(4): 309 - 311. [Abstract] [PDF]
|
|
Article
